Impact of R-Carvedilol on β2-Adrenergic Receptor-Mediated Spontaneous Calcium Release in Human Atrial Myocytes.

arrhythmia calcium spark carvedilol human atrial myocyte sarcoplasmic reticulum β-adrenergic receptor blocker

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
21 Jul 2022
Historique:
received: 02 06 2022
revised: 13 07 2022
accepted: 17 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

A hallmark of atrial fibrillation is an excess of spontaneous calcium release events, which can be mimicked by β1- or β2-adrenergic stimulation. Because β1-adrenergic receptor blockers (β1-blockers) are primarily used in clinical practice, we here examined the impact of β2-adrenergic stimulation on spontaneous calcium release and assessed whether the R- and S-enantiomers of the non-selective β- blocker carvedilol could reverse these effects. For this purpose, human atrial myocytes were isolated from patients undergoing cardiovascular surgery and subjected to confocal calcium imaging or immunofluorescent labeling of the ryanodine receptor (RyR2). Interestingly, the β2-adrenergic agonist fenoterol increased the incidence of calcium sparks and waves to levels observed with the non-specific β-adrenergic agonist isoproterenol. Moreover, fenoterol increased both the amplitude and duration of the sparks, facilitating their fusion into calcium waves. Subsequent application of the non β-blocking R-Carvedilol enantiomer reversed these effects of fenoterol in a dose-dependent manner. R-Carvedilol also reversed the fenoterol-induced phosphorylation of the RyR2 at Ser-2808 dose-dependently, and 1 µM of either R- or S-Carvedilol fully reversed the effect of fenoterol. Together, these findings demonstrate that β2-adrenergic stimulation alone stimulates RyR2 phosphorylation at Ser-2808 and spontaneous calcium release maximally, and points to carvedilol as a tool to attenuate the pathological activation of β2-receptors.

Identifiants

pubmed: 35885069
pii: biomedicines10071759
doi: 10.3390/biomedicines10071759
pmc: PMC9313410
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Spanish Ministry of Science, Innovation and Universities
ID : [SAF2017-88019-C3-1-R]
Organisme : Spanish Ministry of Science, Innovation and Universities
ID : PID2020-116927RB-C21
Organisme : Spanish Ministry of Science, Innovation and Universities
ID : PID2020-116927RB-C22
Organisme : Spanish Ministry of Health, Consume and Social Welfare
ID : CIBERCV [CB16/11/00276]
Organisme : Generalitat de Catalunya
ID : [SGR2017-1769]
Organisme : Fundació Marató TV3
ID : [Marato2015-20-30]
Organisme : Fundació Marató TV3
ID : [Marato2015-20-31]
Organisme : CIHR
ID : (PJT-155940)
Pays : Canada
Organisme : Heart and Stroke Foundation of Canada
ID : (G-19-0026444)
Organisme : Heart and Stroke Foundation of Canada
ID : (END611955)

Références

Pacing Clin Electrophysiol. 2006 Aug;29(8):821-9
pubmed: 16922997
Circulation. 1996 Dec 1;94(11):2807-16
pubmed: 8941106
Lancet. 1998 May 9;351(9113):1406-7
pubmed: 9593418
Eur Heart J. 2011 Mar;32(6):721-9
pubmed: 21177700
J Allergy Clin Immunol. 1999 Aug;104(2 Pt 2):S18-30
pubmed: 10452785
Cardiovasc Res. 2022 Mar 16;118(4):1033-1045
pubmed: 33788918
Circ Res. 2014 Apr 25;114(9):1500-15
pubmed: 24763467
J Clin Invest. 2011 Aug;121(8):2955-68
pubmed: 21804195
N Engl J Med. 1998 Dec 10;339(24):1759-65
pubmed: 9845712
Cardiovasc Drugs Ther. 1999 Apr;13(2):123-6
pubmed: 10372227
Heart Rhythm. 2013 Jan;10(1):101-7
pubmed: 22982970
Circ Res. 2010 Apr 2;106(6):1134-44
pubmed: 20056922
Front Cardiovasc Med. 2019 Jul 12;6:92
pubmed: 31380394
Biochem J. 2015 Sep 1;470(2):233-42
pubmed: 26348911
Circulation. 2022 Feb;145(5):333-344
pubmed: 34874747
Nat Med. 2011 Jul 10;17(8):1003-9
pubmed: 21743453
Eur Heart J. 2012 Aug;33(15):1870-7
pubmed: 22507975
Chirality. 2001 Jul;13(7):342-6
pubmed: 11400186
Acta Physiol (Oxf). 2022 Apr;234(4):e13736
pubmed: 34709723
Eur J Clin Pharmacol. 1990;38 Suppl 2:S104-7
pubmed: 1974497
Cell Signal. 2022 Jan;89:110172
pubmed: 34687901
J Med Chem. 2013 Nov 14;56(21):8626-55
pubmed: 24124794
Circulation. 2003 May 20;107(19):2459-66
pubmed: 12743001
Heart Rhythm. 2009 Apr;6(4):454-60
pubmed: 19324302
Circulation. 2005 Apr 26;111(16):2025-32
pubmed: 15851612
Arch Intern Med. 2004 Jul 12;164(13):1389-94
pubmed: 15249347
Cardiovasc Res. 2019 Mar 1;115(3):578-589
pubmed: 30219899
J Am Coll Cardiol. 2009 Nov 3;54(19):1747-62
pubmed: 19874988
Cardiovasc Res. 2011 Mar 1;89(4):734-43
pubmed: 20943673
Br J Pharmacol. 2010 Jul;160(5):1048-61
pubmed: 20590599
Eur Heart J. 1996 Apr;17 Suppl B:8-16
pubmed: 8733065
Cardiovasc Res. 2019 Dec 1;115(14):1940-1942
pubmed: 31687741
Circ Res. 2021 Jan 22;128(2):246-261
pubmed: 33183171
Pharmacol Rev. 1994 Jun;46(2):121-36
pubmed: 7938162
J Cardiovasc Electrophysiol. 2006 Nov;17(11):1230-8
pubmed: 17074009

Auteurs

Sergi Casabella-Ramón (S)

Instituto de Investigaciones Biomédicas de Barcelona, CSIC, 08036 Barcelona, Spain.
IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
Department of Cell Biology, Physiology and Immunology and Neuroscience Institute, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.

Verónica Jiménez-Sábado (V)

IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
CIBER Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Carmen Tarifa (C)

Instituto de Investigaciones Biomédicas de Barcelona, CSIC, 08036 Barcelona, Spain.
IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Sandra Casellas (S)

Servicio de Cirugía Cardíaca, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.

Tien Tina Lu (TT)

Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.

Paloma Izquierdo-Castro (P)

Instituto de Investigaciones Biomédicas de Barcelona, CSIC, 08036 Barcelona, Spain.
IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.

Ignasi Gich (I)

IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Marcel Jiménez (M)

Department of Cell Biology, Physiology and Immunology and Neuroscience Institute, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
CIBER Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Antonino Ginel (A)

Servicio de Cirugía Cardíaca, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.

José M Guerra (JM)

IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
CIBER Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Servicio de Cardiología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain.

S R Wayne Chen (SRW)

Department of Physiology and Pharmacology, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB T2N 2T9, Canada.

Raul Benítez (R)

Departament d'Enginyeria de Sistemes, Automàtica i Informàtica Industrial, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain.

Leif Hove-Madsen (L)

Instituto de Investigaciones Biomédicas de Barcelona, CSIC, 08036 Barcelona, Spain.
IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
CIBER Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain.

Classifications MeSH